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Summary
Background Sparse data on the safety of pyronaridine-artesunate after repeated treatment of malaria episodes restrict 
its clinical use. We therefore compared the safety of pyronaridine-artesunate after treatment of the ﬁ rst episode of 
malaria versus re-treatment in a substudy analysis.
Methods This planned substudy analysis of the randomised, open-label West African Network for Clinical Trials of 
Antimalarial Drugs (WANECAM) phase 3b/4 trial was done at six health facilities in Mali, Burkina Faso, and Guinea 
in patients (aged ≥6 months and bodyweight ≥5 kg) with uncomplicated microscopically conﬁ rmed Plasmodium spp 
malaria (parasite density <200 000 per μL blood) and fever or history of fever. The primary safety endpoint was 
incidence of hepatotoxicity: alanine aminotransferase of greater than ﬁ ve times the upper limit of normal (ULN) or 
Hy’s criteria (alanine aminotransferase or aspartate aminotransferase greater than three times the ULN and total 
bilirubin more than twice the ULN) after treatment of the ﬁ rst episode of malaria and re-treatment (≥28 days after 
ﬁ rst treatment) with pyronaridine-artesunate. Pyronaridine-artesunate eﬃ  cacy was compared with artemether-
lumefantrine with the adequate clinical and parasitological response (ACPR) in an intention-to-treat analysis. 
WANECAM is registered with PACTR.org, number PACTR201105000286876.
Findings Following ﬁ rst treatment, 13 (1%) of 996 patients had hepatotoxicity (including one [<1%] possible Hy’s law 
case) versus two (1%) of 311 patients on re-treatment (neither a Hy’s law case). No evidence was found that 
pyronaridine-artesunate re-treatment increased safety risk based on laboratory values, reported adverse event 
frequencies, or electrocardiograph ﬁ ndings. For all ﬁ rst treatment or re-treatment episodes, pyronaridine-artesunate 
(n=673) day 28 crude ACPR was 92·7% (95% CI 91·0–94·3) versus 80·4% (77·8–83·0) for artemether-lumefantrine 
(n=671). After exclusion of patients with PCR-conﬁ rmed new infections, ACPR was similar on treatment and re-
treatment and greater than 95% at day 28 and greater than 91% at day 42 in both treatment groups.
Interpretation The ﬁ ndings that pyronaridine-artesunate safety and eﬃ  cacy were similar on ﬁ rst malaria treatment 
versus re-treatment of subsequent episodes lend support for the wider access to pyronaridine-artesunate as an 
alternative artemisinin-based combination treatment for malaria in sub-Saharan Africa.
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Introduction
Malaria remains a major public health issue across sub-
Saharan Africa. The continued availability of aﬀ ordable, 
acceptably safe, and eﬀ ective artemisinin-based com-
bination therapies (ACTs) is necessary to maintain and 
improve recent reductions in malaria morbidity and 
mortality rates.
Pyronaridine-artesunate is an oral ACT for 
Plasmodium falciparum and Plasmodium vivax malaria,1 
and the ﬁ rst antimalarial to receive a positive scientiﬁ c 
opinion from the European Medicines Agency under 
Article 58.2 Pyronaridine-artesunate safety and eﬃ  cacy 
were shown in four phase 3 randomised clinical trials in 
adults and children in Africa and Asia.3–6 In these 
studies, transient increases in liver enzymes were noted 
with pyronaridine-artesunate, typically peaking by day 7 
and normalising by day 28.3–8 Although mostly mild, 
potential Hy’s law events (alanine aminotransferase or 
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aspartate aminotransferase greater than three times the 
upper limit of normal [ULN] plus peak total bilirubin of 
more than twice the ULN)9 were noted in three (<1%) of 
1204 patients treated with pyronaridine-artesunate 
versus one (<1%) of 603 patients receiving artemether-
lumefantrine in two phase 3 studies of P falciparum 
malaria in Africa.3,6 Also, two (<1%) of 1076 patients had 
potential Hy’s law events with pyronaridine-artesunate 
in the two other phase 3 trials (P vivax malaria in Asia 
and P falciparum in Asia and Africa) versus none of 651 
patients in the comparator groups (chloroquine or 
meﬂ oquine-artesunate).4,5 No patient had clinical signs 
of liver injury, and a review by an independent data 
safety monitoring board of potential Hy’s law events 
concluded that the risk of progressive liver injury with 
pyronaridine-artesunate was not a public health concern. 
However, because only a few patients in the phase 3 
studies were re-treated with pyronaridine-artesunate, it 
was unclear whether treatment of repeated malaria 
episodes would exacerbate increases in hepatic enzymes 
or lead to liver injury. Consequently, pyronaridine-
artesunate use was restricted to a single treatment 
course in any patient. To permit wider access to this 
potentially valuable antimalarial drug, more data are 
needed on pyronaridine-artesunate safety and eﬃ  cacy in 
patients re-treated for two or more malaria episodes.
The West African Network for Clinical Trials of 
Antimalarial Drugs (WANECAM) study is a phase 3b/4 
randomised, multicentre, open-label trial of the incidence 
of Plasmodium spp malaria and ACT safety after repeated 
treatment, with each patient receiving the same ACT for 
all malaria episodes over a 2-year follow-up. Pyronaridine-
artesunate and dihydroartemisinin-piperaquine, which 
have not been assessed for the re-treatment of two or 
more malaria episodes, are being compared with the 
ﬁ rst-line ACTs artesunate-amodiaquine or artemether-
lumefantrine, for which results from previous studies 
support malaria re-treatment.10–12 The trial is scheduled to 
be completed in December, 2015.
Here we report the results of a planned analysis of the 
WANECAM dataset at a prespeciﬁ ed timepoint. The 
primary objective was to ascertain if the risk of 
hepatotoxicity with pyronaridine-artesunate was in-
creased on malaria re-treatment versus ﬁ rst treatment. 
For consistency with the phase 3 studies of pyronaridine-
artesunate in children and adults in Africa,3,6 artemether-
lumefantrine was used as a comparator to verify 
pyronaridine-artesunate eﬃ  cacy and safety.
Methods
Study design and participants
The WANECAM study protocol, including details of ten 
protocol amendments, and the substudy statistical 
analysis plan are available from the corresponding 
author. The substudy analysis included patients enrolled 
between Oct 24, 2011, and Oct 31, 2013, at six health 
facilities in Mali (Sotuba, Kolle, and Bougoula-Hameau), 
Burkina Faso (Niankoloko and Bobo-Dioulasso), and 
Guinea (Maferenya).
Male or female patients (aged ≥6 months and 
bodyweight ≥5 kg) were eligible if they had acute 
uncomplicated microscopically conﬁ rmed P falciparum, 
Plasmodium malariae, or Plasmodium ovale malaria 
(<200 000 parasites per μL blood) and fever or a history of 
fever. In the pyronaridine-artesunate group, eligibility 
criteria for age and bodyweight were modiﬁ ed in 
accordance with the planned reviews by the data safety 
monitoring board: at the start of the study, criteria for 
inclusion were age of at least 15 years and bodyweight of at 
least 24 kg; after 20 re-treatments, these criteria were 
revised to at least 2 years and at least 15 kg; after 
40 re-treatments, these criteria were at least 6 months and 
at least 5 kg. For patients randomly allocated to receive 
artemether-lumefantrine, age (≥6 months) and body-
weight (≥5 kg) criteria remained unchanged.
Key exclusion criteria were complicated or severe 
malaria; severe vomiting or diarrhoea; history of clinically 
signiﬁ cant disease or disorders, including known viral 
Research in context
Evidence before this study
The lack of data for the safety and eﬃ  cacy of re-treatment of 
malaria with newly available artemisinin-based combination 
therapies (ACTs) has restricted their use. In phase 2/3 trials of 
pyronaridine-artesunate, transient increases in transaminases 
were noted with pyronaridine-artesunate in some patients after 
a single course of treatment. Whether treatment of repeated 
malaria episodes would exacerbate increases in hepatic enzymes 
or lead to liver injury was not clear. Thus, further data are needed 
on pyronaridine-artesunate safety and eﬃ  cacy in patients 
re-treated for more than one malaria episode.
Added value of this study
The results from this substudy suggest that pyronaridine-
artesunate re-treatment is well tolerated and that the safety 
and eﬃ  cacy of the ﬁ rst malaria treatment episode is maintained 
with re-treatment of patients who have subsequent episodes of 
malaria. Particularly, the risk of a hepatotoxicity event was not 
greater after pyronaridine-artesunate re-treatment versus ﬁ rst 
treatment (0·19% vs 0·54%).
Implications of all the available evidence
These ﬁ ndings support the wider access to pyronaridine-
artesunate as an alternative ACT for malaria treatment in 
sub-Saharan Africa.
For the WANECAM study see 
http://www.wanecam.org/en/
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hepatitis, known HIV infection, or alcohol abuse; hepatic 
or renal impairment; alanine aminotransferase con-
centration of more than twice the ULN; serum creatinine 
concentration of more than 1·5 times the ULN; anaemia 
(haemoglobin <70 g/L); or known hypersensitivity to the 
study drug. Women of childbearing potential had to have 
a negative pregnancy test, not be lactating, and not 
planning pregnancy for 42 days after treatment.
The WANECAM trial is being done in accordance with 
the good clinical practice guidelines and the Declaration 
of Helsinki. Each participating centre’s ethics committee 
or institutional review board approved the study protocol. 
Participants or their parent or guardian provided written 
informed consent plus assent from children able to 
understand the study.
Patients were re-treated with their allocated ACT if they 
presented with malaria at least 28 days after previous 
treatment. An alternative appropriate antimalarial drug 
(usually quinine) was used for any re-treatment if the 
patient had severe malaria; had parasitaemia recurrence 
before 28 days; had Plasmodium spp parasites of more 
than 200 000 per μL; had severe vomiting or diarrhoea; 
had alanine aminotransferase of more than twice the 
ULN; had serum creatinine of more than 1·5 times the 
ULN; had active hepatitis A, B, or C; had an ongoing 
severe adverse event; had arrhythmia or QTc prolongation 
(>450 ms) during previous treatment or at representation; 
was pregnant or breastfeeding; or had other antimalarial 
treatment (except rescue treatment or for severe malaria).
Criteria for treatment discontinuation and study 
withdrawal were a severe drug-related adverse event, 
hypersensitivity to the study drug, drug-related QTc 
prolongation (>450 ms); drug-related alanine amino-
transferase of more than ﬁ ve times the ULN or Hy’s law; 
active chronic hepatitis B or C, or HIV infection; travel 
outside the vicinity of the study for longer than 3 months; 
any other medical disorder compromising the patient’s 
safety; and withdrawal of consent.
Randomisation and masking
The WANECAM study was open label. The microscopists 
assessing the parasite outcomes were masked to 
treatment allocation. At ﬁ rst visit, eligible patients were 
assigned the lowest number on the randomisation list 
for allocation to one of three groups in a 
1:1:1 ratio: pyronaridine-artesunate, dihydroartemisinin-
piperaquine, or ﬁ rst-line ACT comparator (artemether-
lumefantrine or artesunate-amodiaquine). Random isation 
lists were produced using a validated automated system 
by the sponsor. Only patients randomly allocated receive 
to pyronaridine-artesunate or artemether-lumefantrine 
were analysed in this substudy.
Procedures
Pyronaridine-artesunate tablets (180 mg: 60 mg) or 
granule sachets (60 mg: 20 mg), donated by Shin Poong 
Pharmaceutical Company (Ansan, South Korea) and 
artemether-lumefantrine dispersible tablets (20 mg: 
120 mg, Novartis, Basel, Switzerland) and tablets (20 mg: 
120 mg, Novartis) were dosed according to a patient’s 
bodyweight (appendix). Pyronaridine-artesunate was 
administered once a day for 3 days and artemether-
lumefantrine twice a day for 3 days. Both treatments 
were given with water; administration of all doses was 
supervised.
For each episode of malaria, patients were admitted to 
hospital if needed for days 0–3 and actively followed up 
as outpatients on days 7, 14, 21, 28, 35, and 42. Patients 
were also passively followed up for 2-years between active 
follow-up. Study teams were available at health centres 
for 24 h a day to provide health care, including treatment 
for malaria, free of charge to all study participants. Monthly 
home visits ensured that study participants were still 
present in the study area and in good health.
Patients had physical examinations and their vital signs 
were recorded at screening and all subsequent assess-
ments. Adverse events were recorded at all assessments. 
12-lead electrocardiographs were done before treatment, 
on days 2, 3, and 42, and when clinically indicated. Blood 
samples for biochemistry (creatinine, alanine amino-
transferase, alkaline phosphatase, aspartate amino-
transferase, total bilirubin, and con jugated bilirubin) and 
haematology tests were obtained before treatment, 
on days 3, 7, and 28, and when clinically indicated. In the 
event of potential post-treatment hepatotoxicity, 
antihepatitis A IgM, antihepatitis B core IgM, hepatitis B 
surface antigen, hepatitis C RNA, hepatitis E IgM 
antibody, cytomegalovirus PCR testing, pp65 antigen or 
cytomegalovirus IgM antibody, and Epstein-Barr virus 
viral capsid antigen IgM antibody tests were done and 
serum creatinine phosphokinase and lactase 
dehydrogenase were measured.
Parasite species were identiﬁ ed, and parasitaemia was 
deﬁ ned in accordance with WHO’s standards.13 Duplicate 
Giemsa-stained thick and thin blood smears were 
prepared before treatment and every 12 h (samples could 
be taken 2 h either before or after the 12-h point) for up to 
72 h (or two consecutive negative smears) after the ﬁ rst 
dose of treatment, at all follow-up visits, and at treatment 
failure. At each blood smear, triplicate blood samples 
were gathered on 3MM ﬁ lter paper (Whatman Clifton, 
NJ, USA). P falciparum PCR genotyping was done and 
recrudescence was deﬁ ned as at least one matching 
allelic band for P falciparum marker genes between 
baseline samples and samples from recurrences 
after day 7 to day 42.14–16
Outcomes
The primary safety outcome was post-treatment 
hepatotoxicity events in the pyronaridine-artesunate 
group, deﬁ ned as alanine aminotransferase concentration 
greater than ﬁ ve times the ULN or potential case of Hy’s 
law (alanine aminotransferase or aspartate amino-
transferase greater than three times the ULN and total 
See Online for appendix
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bilirubin greater than twice the ULN, conﬁ rmed by the 
data safety monitoring board).9
Other safety outcomes were adverse events, serious 
adverse events (coded using the Medical Dictionary for 
Regulatory Activities [MedDRA], version 16.1), bio-
chemical and haematological values outside the normal 
range, and abnormal QTc from electro cardiographs.
Eﬃ  cacy was assessed with adequate clinical and 
parasitological response (ACPR) as per WHO’s guidelines 
(ie, absence of parasitaemia on day 28 or 42, irrespective of 
axillary temperature, without previously meeting any of the 
criteria of early treatment failure, late clinical failure, or late 
parasitological failure).13 Parasite clearance time for each 
malaria episode was deﬁ ned as the time from treatment 
start until aparasitaemia, maintained for at least 48 h.
Statistical analysis
Pyronaridine-artesunate safety was compared between 
the safety population (all patients who were given at least 
one dose for a ﬁ rst malaria episode) and the safety re-
treatment population (all patients who were given at least 
one dose for any subsequent episode).
The primary safety endpoint was assessed in patients 
having any post-day 0 liver function test for the safety re-
treatment population versus the safety population, 
excluding patients with missing post-day 0 liver function 
test data. Non-inferiority of re-treatment to ﬁ rst treatment 
represented no increased risk of hepatotoxicity events.9 
Simulations showed that 190 re-treated patients would 
have 91·4% power to show non-inferiority of pyronaridine-
artesunate re-treatment to ﬁ rst treatment with a non-
inferiority margin of 5%, with the actual primary endpoint 
event rate of 2·7% after ﬁ rst treatment and re-treatment.
The primary safety endpoint was used as the binary 
dependent variable in a generalised estimating equation 
(GEE) model, dosing (any re-treatment vs ﬁ rst treatment) 
as the ﬁ xed eﬀ ect, and patient as the random eﬀ ect. A 95% 
one-sided upper conﬁ dence limit (95% CI) was computed 
from the GEE model for the diﬀ erence between the 
hepatotoxicity event rate in patients receiving pyronaridine-
artesunate re-treatment minus the hepatotoxicity event 
rate after ﬁ rst treatment. Re-treatment was non-inferior to 
ﬁ rst treatment if the upper conﬁ dence limit was less than 
5%, the pre determined non-inferiority margin.
Eﬃ  cacy was assessed in patients with P falciparum 
malaria receiving at least one dose of study medication 
on ﬁ rst treatment (eﬃ  cacy population) or re-treatment 
(eﬃ  cacy re-treatment population). In the primary eﬃ  cacy 
analysis for ACPR, done on an intention-to-treat basis, 
at day 28 or 42, any failure or missing data equalled 
treatment failure. With a GEE model, overall eﬃ  cacy 
across all malaria episodes was estimated: ACPR 
(success or failure) was the binary dependent variable, 
treatment group (pyronaridine-artesunate or artemether-
lumefantrine) was the ﬁ xed eﬀ ect, and patient was 
random eﬀ ect. 95% CIs were calculated for ACPR from 
the GEE model.
A post-hoc PCR-adjusted ACPR eﬃ  cacy evaluable 
analysis was done with the exclusion of all patients with a 
PCR-conﬁ rmed new P falciparum infection before the 
assessment day; missing data equalled treatment failure. 
Parasite clearance time was estimated with Kaplan-Meier 
analysis. Statistical analyses were done with SAS 
(version 9.3).
WANECAM is registered with PACTR.org, number 
PACTR201105000286876.
Role of the funding source
Principal site investigators and authors from Medicines 
for Malaria Venture developed the protocol, oversaw the 
study, interpreted the data, and developed the report. All 
authors had access to primary data, accept responsibility 
for the accuracy and completeness of data reporting, and 
had ﬁ nal responsibility for the the decision to submit for 
publication.
Results
Figure 1 shows the trial proﬁ le and table 1 shows the 
baseline characteristics of the patients. There were no 
notable diﬀ erences between patients treated with 
pyronaridine-artesunate for a ﬁ rst malaria episode versus 
those who received re-treatment. Also, patients who 
received pyronaridine-artesunate had similar baseline 
characteristics to those who received artemether-
lumefantrine. Of 1015 patients treated with pyronaridine-
artesunate, 316 (31%) were re-treated for 436 malaria 
episodes (re-treatment population; ﬁ gure 1): 232 patients 
were re-treated once, 56 twice, 24 three times, three four 
times, and one patient eight times. Of 671 patients treated 
with artemether-lumefantrine, 238 (35%) were re-treated 
for 344 malaria episodes (ﬁ gure 1): 157 patients were re-
treated once, 61 twice, 16 three times, three four times, and 
one patient ﬁ ve times. P falciparum was detected in 2406 
(99%) of 2439 episodes and 41 (2%) episodes were mixed 
parasite infections.
Liver function was assessed primarily through 
measure ments of alanine aminotransferase, aspartate 
amino transferase, and total bilirubin blood con cen-
trations. Post-day 0 data for liver function tests were 
missing for 19 (2%) of 1015 patients in the pyronaridine-
artesunate safety population and ﬁ ve (2%) of 316 patients 
in the safety re-treatment population (ﬁ gure 1).
13 (1%) of 996 patients had hepatotoxicity events after 
ﬁ rst treatment with pyronaridine-artesunate versus two 
(1%) of 311 after re-treatment (table 2). One potential case 
of Hy’s law occurred after ﬁ rst treatment compared with 
none after re-treatment (table 2).
After the ﬁ rst treatment with pyronaridine-artesunate, 
the incidence of hepatotoxicity events was higher in 
patients aged 18 years and older (four [4%] of 112) versus 
those younger than 18 years (nine [1%] of 884; table 2) and 
in patients with bodyweights of at least 20 kg (ten [2%] of 
617) versus those with a bodyweight of less than 20 kg 
(three [1%] of 379). Three patients with hepatotoxicity 
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5981 patients screened
3850 randomly allocated to treatment groups
1686 randomly allocated to substudy
2164 not included in substudy
447 did not receive 
 retreatment  
433 did not receive 
 retreatment  
699 did not receive 
 retreatment  
226 pyronaridine-artesunate retreatment 
         for 325 malaria episodes (eﬃcacy 
         retreatment population) 
         215 with P falciparum eﬃcacy assessed 
            11 did not have P falciparum 
238 artemether-lumefantrine
          retreatment for 344 malaria episodes
          (safety and eﬃcacy retreatment 
          population)
         238 with P falciparum eﬃcacy assessed
316 pyronaridine-artesunate retreatment 
         for 436 malaria episodes (safety 
           retreatment population)
 311 hepatotoxicity assessed with
 post-day 0 liver function test data 
 1 lost to follow-up
 4 incomplete dosing
  1 vomiting
  3 other
Pyronaridine-artesunate versus
non-artemether-lumefantrine 
artemisinin-based combination treatment 
(artesunate-amodiaquine)
Pyronaridine-artesunate versus 
artemether-lumefantine
342 randomly allocated to 
        pyronaridine-artesunate group 
         144 Burkina Faso (Niankoloko)
        198 Guinea (Maferenya)
673 randomly allocated to 
         pyronaridine-artesunate group
         224 Burkina Faso (Bobo-Dioulasso)
         449 Mali
                  215 Bougoula-Hameau
                     87 Kolle
                  147 Sotuba
671 randomly allocated to 
          artemether-lumefantrine group
          224 Burkina Faso (Bobo-Dioulasso)
          447 Mali
                   213 Bougoula-Hameau 
                     87 Kolle
                   147 Sotuba 
1015 pyronaridine-artesunate for malaria
           episode 1 (safety population)
 996 hepatotoxicity assessed with 
 post-day 0 liver function test data
 9 withdrew from study
  4 consent withdrawn
  2 adverse events
  1 protocol violation
  2 other
 10 incomplete dosing
  7 vomiting
  3 other
673 pyronaridine-artesunate for malaria 
         episode 1 (eﬃcacy population)
         665  with P falciparum eﬃcacy assessed
               8 did not have P falciparum
671 artemether-lumefantrine for malaria 
         episode 1 (safety and eﬃcacy 
         population)
         667 with P falciparum eﬃcacy assessed
              4 did not have P falciparum
2131 excluded
 925 malaria not conﬁrmed
 259 electrocardiogram or QTc criteria not met
 191 unsuitable
 127 haematological criteria not met
   99 no consent
   91 local operational issues
   87 severe malaria
   81 increased liver enzymes
 271 other clinical reason
Figure 1: Trial proﬁ le
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events after ﬁ rst treatment were re-treated by mistake with 
pyronaridine-artesunate without recurrence of any 
hepatotoxicity event.
On re-treatment with pyronaridine-artesunate, two 
patients aged 10 years and 45 years with bodyweights of 
at least 20 kg had hepatotoxicity events after the second 
episode of malaria. One of these patients was re-treated 
with pyronaridine-artesunate by mistake without 
recurrence of any hepatotoxicity event.
Analysis of all available laboratory values with the 
GEE model provided an estimated treatment diﬀ erence 
for the hepatotoxicity event rate of –0·36% (one-sided 
95% CI 0·03) between re-treatment (0·19%) and ﬁ rst 
treatment (0·54%). Based on the post-treatment worse 
case per episode, the GEE estimate for the treatment 
diﬀ erence in hepatotoxicity event rate was −0·84% (one-
sided 95% CI 0·03) between re-treat ment (0·47%) and 
ﬁ rst treatment (1·31%). In both analyses, conﬁ rmation 
of non-inferiority between re-treatment and ﬁ rst 
treatment suggested no increase in hepatotoxicity event 
rate on re-treatment with pyronaridine-artesunate 
versus ﬁ rst treatment.
Scatter plots of peak concentrations of total bilirubin 
versus peak concentrations of alanine aminotransferase 
or aspartate aminotransferase conﬁ rmed that there were 
no greater increases in concentrations of liver enzymes 
on re-treatment with pyronaridine-artesunate versus ﬁ rst 
treatment (ﬁ gure 2). All hepatotoxicity events resolved 
by day 28 without clinical sequelae (one patient withdrew 
consent before day 28).
After the ﬁ rst treatment with pyronaridine-artesunate, 
adverse events from any cause occurred in 429 (42%) of 
1015 patients versus 118 (37%) of 316 patients after re-
treatment. 225 (52%) of 436 episodes were re-treated 
with pyronaridine-artesunate within 28–60 days after the 
ﬁ rst treatment, 80 (18%) of 436 were re-treated after 
60–90 days, and 131 (30%) of 436 after 90 days (median 
64 days, range 28–452). Within 28–60 days after ﬁ rst 
treatment, the incidence of adverse events tended to 
decrease on re-treatment (ﬁ gure 3).
All patients Age ≥6 months to 
<5 years
Age ≥5years to <18 years Age ≥18 years
Episode 1 Episode 2+ Episode 1 Episode 2+ Episode 1 Episode 2+ Episode 1 Episode 2+
Patients dosed 1015 316 236 78 666 201 113 37
Total number of post-day 0 liver function tests 2894 1215 652 276 1922 789 320 150
Number of hepatotoxicity events* 16 (1%) 2 (<1%) 5 (1%) 0 (0%) 6 (<1%) 1 (<1%) 5 (2%) 1 (1%)
Patients with any post day 0 liver function test 996 311 224 78 660 197 112 36
Patients with hepatotoxicity events 13 (1%) 2 (1%) 3 (1%) 0 6 (<1%) 1 (1%) 4 (4%) 1 (3)
Potential Hy’s law event† 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Data are number or number (%). *Denominator for the calculation of the percentages was total number of post-day 0 liver function tests. †Denominator for the calculation 
of the percentages was the number of patients dosed.
 Table 2: Incidence of hepatotoxicity events at any post-dosing timepoint after treatment with pyronaridine-artesunate for a ﬁ rst malaria episode 
(episode 1) versus re-treatment (episode 2+)
Pyronaridine-artesunate safety analysis Comparative eﬃ  cacy analysis
Safety population* 
(n=1015)
Safety re-treatment 
population† (n=316)
Pyronaridine-artesunate 
(n=673)
Artemether-lumefantrine 
(n=671)
Sex, female 509 (50%) 149 (47%) 328 (49%) 319 (48%)
Age (years)
Mean (SD, range) 10·1 (8·6, 0–62) 10·3 (8·5, 0–56) 11·8 (9·4, 1–62) 11·7 (9·7, 0–69)
<5 236 (23%) 78 (25%) 116 (17%) 130 (19%)
≥5 to <18 666 (66%) 201 (64%) 453 (67%) 443 (66%)
≥18 years 113 (11%) 37 (12%) 104 (15%) 98 (15%)
Bodyweight (kg)
Mean (SD, range) 28·7 (16·6, 6·7–84·2) 29·5 (17·7, 7·0–82·0) 32·0 (17·7, 8·3–84·2) 31·8 (18·2, 7·8–100·6)
<20 393 (39%) 128 (41%) 213 (32%) 233 (35%)
≥20 622 (61%) 188 (59%) 460 (68%) 438 (65%)
Geometric mean parasite count 
(ﬁ rst episode) per μL (IQR)
36 092 (1650–51 220) 38 905 (3010–52 080) 38 865 (4500–53 040) 40 918 (4740–56 160)
Data are number (%), unless otherwise indicated. *Included all patients who received at least one dose of pyronaridine-artesunate for treatment of a ﬁ rst malaria episode. 
†Included all patients who received at least one dose of pyronaridine-artesunate for the ﬁ rst malaria episode plus at least one dose of pyronaridine-artesunate for a 
subsequent malaria episode.
 Table 1: Baseline characteristics of patients
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No trends were noted in the type or incidence of adverse 
events on ﬁ rst treatment with pyronaridine-artesunate 
versus re-treatment (table 3). 3% of 1015 patients had 
increases in aspartate aminotransferase concentrations 
and 3% had increases in alanine aminotransferase 
concentrations after ﬁ rst treatment, and 3% and 2% of 
316, respectively, had increases after re-treatment (table 3). 
187 (18%) of 1015 patients had drug-related adverse events 
on ﬁ rst treatment with pyronaridine-artesunate versus 
45 (14%) of 316 after re-treatment.
After the ﬁ rst treatment with pyronaridine-artesunate, 
11 (1%) of 1015 patients had at least one serious adverse 
event versus two (1%) of 316 on re-treatment. With the 
exception of an unrelated death from trauma, all adverse 
events resolved without further sequelae. Five patients 
had serious adverse events, all on ﬁ rst treatment, that 
were thought to be drug related: anaemia and malaria in a 
3-year-old girl; alanine aminotransferase 852 IU/L and 
aspartate aminotransferase 298 IU/L at day 7 in a 2-year-
old girl; alanine aminotransferase 339 IU/L and aspartate 
aminotransferase 417 IU/L at day 35 in a 3-year-old boy; 
aspartate aminotransferase 196 IU/L, alanine amino-
transferase 379 IU/L, and bilirubin 38 μmol/L, which the 
data safety monitoring board discounted as a Hy’s law 
case because of the high baseline bilirubin concentration 
(46 μmol/L), in a 31-year old woman; and peak alanine 
aminotransferase 1229 IU/L, aspartate aminotransferase 
890 IU/L, and bilirubin 41 μmol/L on day 7, alkaline 
phosphatase 571 IU/L on day 7, which peaked at 901 IU/L 
on day 14, in a 2-year-old girl. The data safety monitoring 
board concluded that this event was an acute hepatocellular 
liver injury (ie, potential Hy’s law case), possibly 
exacerbated by concomitant metamizole administration, 
and was followed by substantial improvement.
The safety proﬁ le of artemether-lumefantrine was as 
expected (table 3). After ﬁ rst treatment, 45% of 
671 patients had adverse events (table 3), and 127 (19%) 
were thought to be drug related. Five (1%) of 671 patients 
had serious adverse events and one adverse event was 
thought to be drug related (toxic epidermal necrolysis). 
One patient had a serious adverse event (liver injury: 
alanine aminotransferase 298 IU/L, aspartate amino-
transferase 195 IU/L, and bilirubin 48 μmol/L—ie, 
potential Hy’s law event), but was not thought to be drug 
related because it occurred on day 56.
Two patients died during the study, but neither death 
was thought to be drug related: road traﬃ  c accident (in 
the pyronaridine-artesunate group), and pneumopathy 
and immunosuppression caused by HIV infection (in 
the artemether-lumefantrine group).
Risk of Fridericia-corrected QTc (QTcF) prolongation was 
not increased with repeated pyronaridine-artesunate 
treatment (table 4). Four patients had QTcF prolongation of 
at least 30 ms for two treatment episodes (two consecutive 
and two non-consecutive). These male patients were aged 
16–21 years with QTcF prolonged by 35–86 ms versus 
baseline, but values did not exceed 450 ms (396–437).
Risk of QTcF on repeated treatment with artemether-
lumefantrine was not increased versus ﬁ rst treatment 
(table 4). Four patients had QTcF prolongation of at least 
30 ms for two treatment episodes (all consecutive 
episodes 1 and 2). Two patients were boys, aged 9 years 
and 15 years, and two were girls aged 2 years and 10 years, 
with QTcF prolonged by 33–70 ms versus baseline, but 
values did not exceed 450 ms (390–446) .
In a conservative intention-to-treat eﬃ  cacy analysis of 
patients with P falciparum infection using a GEE model, 
across all treatment and re-treatment episodes, day-28 
crude ACPR was 92·7% (95% CI 91·0–94·3) with 
pyronaridine-artesunate and 80·4% (77·8–83·0) with 
artemether-lumefantrine (treatment diﬀ erence 12·3%, 
95% CI 9·1–15·4; p<0∙0001). Day 42 ACPR was 77·3% 
(74·5–80·1) versus 65·4% (62·2–68·5), respectively 
(12·0%, 7·7–16·2; p<0∙0001; appendix). After exclusion of 
patients with PCR-conﬁ rmed new infections, ACPR was 
similar between pyronaridine-artesunate and artemether-
lumefantrine treatments and greater than 95% at day 28 
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and greater than 91% at day 42 in both treatment groups 
(appendix).
Median parasite clearance time with pyronaridine-
artesunate was shorter for the ﬁ rst treatment episode 
(24·8 h, 95%CI 24·3–33·9) than with artemether-
lumefantrine (34·5 h, 34·2–35·2), but similar for 
subsequent episodes (appendix).
Discussion
The results of the primary safety analysis for this substudy 
conﬁ rmed that the risk of a hepatotoxicity event was not 
greater after pyronaridine-artesunate re-treatment versus 
ﬁ rst treatment (0·19% vs 0·54%). The safety proﬁ les of 
pyronaridine-artesunate and artemether-lumefantrine in 
this study were consistent with those in previous 
comparative phase 2 and 3 trials.3–8 In previous trials, 
transient increases in transaminases were noted after one 
course of pyronaridine-artesunate in some patients.
In our study, laboratory deﬁ ned hepatotoxicity events 
occurred in some patients, but without clinical 
manifestations and the outcomes were favourable. There 
was no indication of any increased risk of hepatoxicity on 
re-treatment of patients with bodyweights of less than 
20 kg versus those 20 kg or greater or for those younger 
than 18 years versus older patients. Although hepatotoxicity 
events were more common in patients older than 18 years, 
three of four hepatic-related serious drug-related adverse 
events were in children up to 3 years of age.
Pyronaridine-artesunate re-treatment did not increase 
overall safety risk based on adverse event frequencies, 
laboratory values, or electrocardiograph ﬁ ndings. The 
half-life of pyronaridine is about 14 days so the period 
between exposures could be aﬀ ected by residual blood 
concentrations (ﬁ ve half-lives equal to 60 days). However, 
there was no evidence of increased risk according to time 
between treatments. Thus, because more than 50% of 
patients were re-treated with pyronaridine-artesunate 
within 28–60 days of the ﬁ rst treatment, the safety 
ﬁ ndings lend support for re-treatment of patients at least 
28 days after previous exposure.
Eﬃ  cacy was assessed in an intention-to-treat analysis 
and outcomes were consistent with this conservative 
approach. For crude ACPR, overall eﬃ  cacy was higher 
with pyronaridine-artesunate than with artemether-
lumefantrine treatment. However, after exclusion of 
patients with new infections, the results of PCR-adjusted 
ACPR were consistent with the ﬁ ndings from two 
previous phase 3 trials, showing similar eﬃ  cacy for the 
two agents.3,6 Thus, the diﬀ erence in crude ACPR 
resulted from a higher re-infection rate in the artemether-
lumefantrine group than in the pyronaridine-artesunate 
group and might be explained by the longer elimination 
half-life of pyronaridine (14 days) than of lumefantrine 
(3–4 days).17 Notably, both ACTs met the WHO criteria of 
greater than 95% PCR-adjusted ACPR at day 28.18
As with most clinical trials, patients were excluded on 
the basis of criteria that were applicable to real-life 
settings—ie, pre-existing increased liver function tests 
or hepatitis. Thus, additional studies might be needed 
to obtain comprehensive safety information in these 
populations. Also, patients who had hepatotoxicity 
events on ﬁ rst treatment with pyronaridine-artesunate 
were to be excluded from subsequent treatment. Four 
patients who had a hepatotoxicity event after 
pyronaridine-artesunate were re-treated with the same 
drug by mistake and none had another hepatotoxicity 
event or any hepatic related adverse event. These errors 
occurred because of absence of any clinical symptoms 
and delay in drawing attention to the abnormal 
laboratory values. In the 15 patients who had 
hepatotoxicity events with pyronaridine-artesunate, 
although a panel of hepatic assessments should have 
Pyronaridine-artesunate group Artemether-lumefantrine group
Episode 1 
(n=1015)
Episode 2+ 
(n=316)
Episode 1 
(n=671)
Episode 2+ 
(n=238)
Any events 429 (42%) 118 (37%) 303 (45%) 96 (40%)
Aspartate aminotransferase increased 29 (3%) 10 (3%) 10 (1%) 1 (<1%)
Alanine aminotransferase increased 28 (3%) 5 (2%) 7 (1%) 2 (1%)
Hypercreatinaemia 16 (2%) 7 (2%) 16 (2%) 8 (3%)
Hyperbilirubinaemia 2 (<1%) 0 (0%) 2 (<1%) 2 (1%)
Drug-induced liver injury 1 (<1%) 0 (0%) 1 (<1%) 0 (0%)
Electrocardiogram QT prolonged 28 (3%) 10 (3%) 43 (6%) 7 (3%)
Abdominal pain 34 (3%) 3 (1%) 16 (2%) 0 (0%)
Vomiting 33 (3%) 4 (1%) 10 (1%) 3 (1%)
Diarrhoea 10 (1%) 0 (0%) 2 (<1%) 0 (0%)
Neutropenia 34 (3%) 7 (2%) 25 (4%) 12 (5%)
Anaemia 22 (2%) 3 (1%) 24 (4%) 2 (1%)
Monocytosis 13 (1%) 3 (1%) 12 (2%) 8 (3%)
Thrombocytopenia 8 (1%) 4 (1%) 5 (1%) 0 (0%)
Data are number (%). Data for artemether-lumefantrine are shown for reference.
 Table 3: Adverse events of interest from any cause after pyronaridine-artesunate treatment of a ﬁ rst 
malaria episode (episode 1) versus re-treatment (episode 2+)
Pyronaridine-artesunate Artemether-lumefantrine
Episode 1 (n=396) Episode 2+ (n=126) Episode 1 (n=192) Episode 2+ (n=71)
Highest post-dose increase versus day 0
≤0 ms 129 (33%) 30 (24%) 30 (16%) 10 (14%)
>0–<30 ms 174 (44%) 65 (52%) 90 (47%) 30 (42%)
30–60 ms 45 (11%) 17 (13%) 43 (22%) 17 (24%)
>60 ms 5 (1%) 2 (2%) 3 (2%) 3 (4%)
Data missing 43 (11%) 12 (10%) 26 (14%) 11 (15%)
Any post-dose value
>450 ms 0 (0%) 2 (2%) 0 (0%) 2 (3%)
>480 ms 0 (0%) 0 (0%) 0 (0%) 1 (1%)
>500 ms 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Data are number (%). Numbers represent patients who were assessable. Data for artemether-lumefantrine are shown 
for reference.
 Table 4: Categorical QT values corrected with Fridericia’s formula after pyronaridine-artesunate 
treatment of a ﬁ rst malaria episode (episode 1) versus re-treatment (episode 2+)
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The similar safety and eﬃ  cacy of pyronaridine-
artesunate on ﬁ rst treatment of malaria versus re-
treatment of subsequent malaria episodes lend support to 
wider access to pyronaridine-artesunate as an alternative 
ACT for the treatment of malaria in sub-Saharan Africa.
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